In this clip from the National Association of Pediatric Nurse Practitioners in New Orleans, Mary Koslap‐Petraco DNP, PNPPC‐BC, CPNP, FAANP of Stony Brook University School of Nursing and Pediatric Nurse Practitioner House Calls explains 2 new vaccine-preventable disease treatment options that will be available soon.
Transcript
Mary Koslap-Petraco, DNP: Well, there are 2 new vaccine-preventable disease options that are on the horizon. There is a new anti-viral that was just was just recently licensed for when someone comes with influenza. The only issue for children is that it's only licensed for 12 years of age and older, but it has a very low side-effect profile. The other issue with it also is that-it might even be better than some of the old anti-virals, because it decreases the time of illness by 54 hours, rather than the 24 hours that we had with the previous anti-virals. It's also effective against some of the virus strains that are now starting to show some resistance to some of the older anti-viral drugs.
The other drug that is on the horizon is the RSV vaccination. We never had RVS vaccination before, and this drug that they're working on now is going to be only one shot. Of course for the high-risk babies first, but it may be even broader than that, but it's being fast-tracked through the FDA, which will be wonderful for those babies that are at-risk for RSV disease.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.
Pfizer Announces Positive Top-Line Data for Abrysvo Immunization in Adults Aged 18 to 59 Years
April 9th 2024Abrysvo is currently approved to treat RSV-associated lower respiratory tract disease in adults aged 60 years and older, and in infants through the immunization of pregnant individuals.